

## Intra-Cellular Therapies Appoints Mark Neumann as Executive Vice President, Chief Commercial Officer

October 16, 2018

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Mark Neumann as Executive Vice President, Chief Commercial Officer. Mr. Neumann has over 30 years of biopharmaceutical industry experience with a strong track record of building high-performing commercial teams and successfully executing numerous product launches across a range of therapeutic areas including specialty and primary care businesses.

Mr. Neumann joins ITCI from Amgen where he was initially recruited as Vice President, Marketing to build and establish a new U.S. cardiovascular business unit, and launch Amgen's first ever cardiovascular medicines. In his most recent role as Vice President, Global Marketing with leadership of nephrology, inflammation, and bone health, Mr. Neumann was responsible for conceiving therapeutic area strategies, developing marketing platforms for global launches and directing commercial assessments for external business development opportunities.

Prior to Amgen, Mr. Neumann spent 25 years at Bristol-Myers Squibb (BMS) and held senior U.S. and global commercial roles in neuroscience, cardiovascular and diabetes. During his tenure at BMS he led sales and marketing for the U.S. neuroscience business unit, and delivered strong growth of the antipsychotic Abilify. He also held the position of Vice President, Global Commercialization for neuroscience where he established a new worldwide disease area strategy and directed the commercialization of neuroscience pipeline assets. Mark received his Bachelor of Arts in Economics and Business Administration degree from Lafayette College.

"Mark is a proven leader with broad experience developing and implementing commercial strategies for early and late-stage assets within neuroscience and cardiovascular therapeutic fields. We believe his expertise further strengthens and complements our growing organization as we prepare for the commercialization of lumateperone and further advance our pipeline," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

"I am very excited to join the leadership team at Intra-Cellular Therapies and look forward to leading the commercial organization as we advance the launch preparations for lumateperone as well as developing commercial strategies for the Company's pipeline," said Mr. Neumann.

### About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with Alzheimer's disease, depression, and other neuropsychiatric and neurological disorders. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company's PDE1 portfolio, ITI-214, is in development for the treatment of Parkinson's disease and heart failure.

### INVESTORS:

Intra-Cellular Therapies, Inc.  
Juan Sanchez, M.D.  
Vice President, Corporate Communications and Investor Relations  
646-440-9333

Burns McClellan, Inc.  
Lisa Burns  
[agray@burnsmc.com](mailto:agray@burnsmc.com)  
212-213-0006

MEDIA INQUIRIES:  
Patrick Ryan, Esq.  
Corporate Media Relations, WCG World  
[pryan@wcgworld.com](mailto:pryan@wcgworld.com)



Source: Intra-Cellular Therapies Inc.